Clinical Nutrition for Cancer Care Global Market Report 2024

The clinical nutrition for cancer care market size has grown strongly in recent years. It will grow from $4.67 billion in 2023 to $4.92 billion in 2024 at a compound annual growth rate (CAGR) of 5.5%. The growth observed in the historic period can be attributed to heightened awareness of nutritional needs, the rise of precision nutrition methods, changes in healthcare policies and reimbursement models, surgical cancer interventions, and increasing interest in functional foods, nutraceuticals, and dietary supplements.

The clinical nutrition for cancer care market size is expected to see strong growth in the next few years. It will grow to $6.14 billion in 2028 at a compound annual growth rate (CAGR) of 5.7%. The growth in the forecast period is expected to result from a shift towards personalized medicine and precision nutrition, higher demand for clinical nutrition interventions to support patients, greater awareness of nutrition's impact on cancer treatment outcomes, advancements in cancer treatments, and the integration of structured clinical nutrition pathways in oncology. Key trends for the forecast period include progress in nutritional biomarker research, technological innovations in nutritional products and delivery systems, enhanced collaboration among oncologists, ongoing advancements in nutritional science, and continued research and development in the field.

The increasing prevalence of cancer is expected to drive the growth of the clinical nutrition for cancer care market in the future. Cancer encompasses a range of diseases characterized by uncontrolled cell growth and the potential for metastasis. The rise in cancer cases is largely due to increased life expectancy, resulting in a larger aging population more vulnerable to cancer. Clinical nutrition for cancer care involves specialized dietary management and nutritional support tailored to the unique needs of cancer patients to optimize treatment outcomes. For example, in February 2024, the World Health Organization, an intergovernmental organization based in the US, projected approximately 35 million new cancer cases by 2050, a 77% increase from the estimated 20 million cases in 2022. Consequently, the growing prevalence of cancer is fueling the expansion of the clinical nutrition for cancer care market.

Leading companies in the clinical nutrition for cancer care market are innovating products for cancer patients, such as oral nutritional supplements, to gain a competitive advantage. Oral nutritional supplements are specially formulated dietary products designed to provide targeted nutritional support for individuals with specific medical conditions. For instance, in July 2022, Nestle, a Switzerland-based food and drink processing company, introduced China's first Foods Oral Impact Su Yi Su. This product contains arginine and fish omega-3, along with other basic nutritional ingredients for special medical purposes (FSMP) for patients with tumor-related conditions, following a five-year approval process by the Chinese regulator. Oral Impact Su Yi Su is a FSMP nutritional supplement specifically approved to meet the unique nutritional needs of individuals undergoing cancer treatment.

In January 2024, Danone S.A., a French food-products corporation, partnered with Resilience to create a groundbreaking nutrition and oncology module integrated into Resilience's digital oncology solution. This partnership aims to improve nutritional care for cancer patients by addressing cancer-related malnutrition, which affects up to 70% of cancer patients. Resilience, a US-based digital oncology company, offers clinical nutrition support for cancer patients.

Major companies operating in the clinical nutrition for cancer care market are Pfizer Inc., Bayer AG, Abbott Nutrition, GlaxoSmithKline plc, Reckitt Benckiser Group plc, Evonik Industries AG, Baxter International Inc., Otsuka Holdings Co. Ltd., B. Braun Melsungen AG, Koninklijke DSM N.V., Glanbia plc, Kyowa Kirin Co. Ltd, Nestle Health Science S.A., Danone Nutricia, BioGaia AB, Meiji Holdings Company Ltd., Hormel Health Labs, Victus Inc., Taiho Pharmaceutical Co. Ltd., Global Health Products Inc.

North America was the largest region in the clinical nutrition for cancer care market in 2023. The regions covered in the clinical nutrition for cancer care market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the clinical nutrition for cancer care market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Clinical nutrition for cancer care involves specialized dietary support and interventions tailored to address the nutritional needs of cancer patients throughout their treatment journey. This includes personalized nutrition plans designed to manage symptoms, optimize treatment outcomes, and enhance the overall quality of life for individuals undergoing cancer therapy.

The primary types of clinical nutrition for cancer care include oral nutrition, parenteral nutrition, and enteral feeding formulas. Oral nutrition refers to the consumption of food and fluids by mouth to provide essential nutrients, crucial for supporting those undergoing cancer treatment. This approach is applicable to various cancer types, such as head and neck cancer, stomach and gastrointestinal cancers, blood cancer, breast cancer, lung cancer, and others, for both adults and children. Clinical nutrition for cancer care is distributed through sales channels such as online platforms, retail outlets, and institutional sales.

The clinical nutrition for cancer care market research report is one of a series of new reports that provides clinical nutrition for cancer care market statistics, including the clinical nutrition for cancer care industry global market size, regional shares, competitors with the clinical nutrition for cancer care market share, detailed clinical nutrition for cancer care market segments, market trends, and opportunities, and any further data you may need to thrive in the clinical nutrition for cancer care industry. These clinical nutrition for cancer care market research reports deliver a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The clinical nutrition for cancer care market consists of sales of clinical nutrition products such as high-protein supplements and dietary supplements rich in antioxidants, vitamins, and minerals. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.